Table2_Characterization of Hypoxia-Related Molecular Subtypes in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy and Targeted Therapy via Multi-Omics Analysis.XLSX
Objective: Tumor hypoxia is a key factor in resistance to anti-cancer treatment. Herein, this study aimed to characterize hypoxia-related molecular subtypes and assess their correlations with immunotherapy and targeted therapy in clear cell renal cell carcinoma (ccRCC).
Materials: We comprehensively analyzed copy number variation (CNV), somatic mutation, transcriptome expression profile and clinical information for ccRCC from TCGA and ICGC databases. Based on 98 prognosis-related hypoxia genes, samples were clustered using unsupervized non-negative matrix factorization (NMF) analysis. We characterized the differences between subtypes concerning prognosis, CNV, somatic mutations, pathways, immune cell infiltrations, stromal/immune scores, tumor purity, immune checkpoint inhibitors (ICI), response to immunotherapy and targeted therapy and CXC chemokines. Based on differentially expressed genes (DEGs) between subtypes, a prognostic signature was built by LASSO Cox regression analysis, followed by construction of a nomogram incorporating the signature and clinical features.
Results: Two hypoxia-related molecular subtypes (C1 and C2) were constructed for ccRCC. Differential CNV, somatic mutations and pathways were found between subtypes. C2 exhibited poorer prognosis, higher immune/stromal scores, and lower tumor purity than C1. Furthermore, C2 had more sensitivity to immunotherapy and targeted therapy than C1. The levels of CXCL1/2/3/5/6/8 chemokines in C2 were distinctly higher than in C1. Consistently, DEGs between subtypes were significantly enriched in cytokine-cytokine receptor interaction and immune responses. This subtype-specific signature can independently predict patients’ prognosis. Following verification, the nomogram could be utilized for personalized prediction of the survival probability.
Conclusion: Our findings characterized two hypoxia-related molecular subtypes for ccRCC, which can assist in identifying high-risk patients with poor clinical outcomes and patients who can benefit from immunotherapy or targeted therapy.
History
References
- https://doi.org//10.1016/j.ctrv.2018.07.009
- https://doi.org//10.1002/ijc.29519
- https://doi.org//10.1016/j.eururo.2011.10.007
- https://doi.org//10.1182/blood-2005-08-3182
- https://doi.org//10.1038/nature12222
- https://doi.org//10.3390/cancers12010016
- https://doi.org//10.3390/cancers11071000
- https://doi.org//10.1111/imm.12917
- https://doi.org//10.18637/jss.v033.i01
- https://doi.org//10.1186/1471-2105-11-367
- https://doi.org//10.1056/NEJMoa1113205
- https://doi.org//10.1186/1471-2105-14-7
- https://doi.org//10.1038/nrdp.2017.9
- https://doi.org//10.1016/j.ymthe.2020.04.023
- https://doi.org//10.1007/s00432-020-03299-3
- https://doi.org//10.1186/s12943-019-1089-9
- https://doi.org//10.1126/science.1132939
- https://doi.org//10.1093/bioinformatics/bts034
- https://doi.org//10.1001/jamaoncol.2017.1609
- https://doi.org//10.18632/aging.102161
- https://doi.org//10.1152/physrev.00018.2019
- https://doi.org//10.1093/nar/gkv007
- https://doi.org//10.1186/s13059-016-1092-z
- https://doi.org//10.1016/j.ejca.2019.04.003
- https://doi.org//10.3322/caac.21551
- https://doi.org//10.1073/pnas.0506580102
- https://doi.org//10.3390/cells9040992
- https://doi.org//10.1186/s40425-019-0810-y
- https://doi.org//10.18632/aging.102233
- https://doi.org//10.1093/nar/gks1111
- https://doi.org//10.1038/s42255-019-0045-8
- https://doi.org//10.1038/ncomms3612
- https://doi.org//10.1089/omi.2011.0118
- https://doi.org//10.3389/fonc.2019.01555
- https://doi.org//10.1126/science.aap8411
- https://doi.org//10.1016/j.isci.2020.101460
